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Abstract
Objective: To compare psychosocial outcomes (follow-up related worries and satisfaction with follow-
up related information and support) over 30 months of two alternative management policies for
women with low-grade abnormal cervical cytology.
Methods: Women aged 20–59 years with low-grade cytological abnormalities detected in the
National Health Service Cervical Screening Programme were randomised to cytological surveillance
or initial colposcopy. A total of 3399 women who completed psychosocial questionnaires at recruit-
ment were invited to complete questionnaires at 12, 18, 24 and 30 months. Linear mixed models were
used to investigate differences between arms in the two psychosocial outcomes. Each outcome had a
maximum score of 100, and higher scores represented higher psychosocial morbidity.
Results: On average, over 30 months, women randomised to colposcopy scored 2.5 points (95%CI
3.6 to 1.3) lower for follow-up related worries than women randomised to cytological surveillance.
Women in the colposcopy arm also scored signiﬁcantly lower for follow-up related satisfaction with
information and support (2.4; 3.3 to 1.4) over 30 months. For both outcomes, the average differ-
ence between arms was greatest at 12th- and 18th-month time points. These differences remained
when the analysis was stratiﬁed by post-school education.
Conclusions: Women with low-grade cytology, irrespective of their management, have substantial
initial psychosocial morbidity that reduces over time. Implementation of newer screening strategies,
which include surveillance, such as primary HPV screening, need to consider the information and sup-
port provided to women.
© 2016 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
Introduction
Many women have an abnormal cervical screening test,
based on cytological and/or human papilloma virus (HPV)
testing. Irrespective of the nature of the initial test, abnormal
screens require further investigation. A range of options ex-
ist, the main ones being repeat testing (by cytology and/or
HPV) and colposcopy examination. Both are recognised
as acceptable in a range of guidelines internationally [1–4].
Like all screenings, cervical screening involves a balance
between harms and beneﬁts. Harms include adverse
psychosocial sequelae identiﬁed across the entire screening
process from initial screening, investigation and potentially
beyond [5]. Psychosocial distress associated with alterna-
tive management policies has been little investigated. The
debate about relative levels of anxiety between repeat
testing (i.e. surveillance) and colposcopy has been ongoing
for at least two decades [6,7], but there are only two
randomised trials of women with low-grade cytology. The
ﬁrst found no difference at 12 months in mean distress or
anxiety scores (assessed using the General Health Question-
naire and the Spielberger State Trait Anxiety Inventory)
© 2016 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
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between those women randomised to a repeat cytology test
in 6 months or a choice between repeat cytology and an im-
mediate colposcopy [8]. The second trial (known as
TOMBOLA) found no difference in anxiety or depression
(assessed using the Hospital Anxiety and Depression Scale
(HADS)) over 30 months of follow-up between women
randomised to cytological surveillance or initial colpos-
copy, although anxiety and depression were signiﬁcantly
lower in women in the colposcopy arm at 6 weeks [9].
A potential limitation of these reports is they considered
generalised measures of psychosocial morbidity. Women
attending for cervical screening report a range of speciﬁc
concerns, including worries about cervical cancer, fertility,
psychosexual issues and body image, and it is likely that
generalised measures of anxiety and depression do not
capture these adequately [10]. Furthermore, it is possible
that, in the same women, patterns of generalised anxiety
and patterns of these more speciﬁc concerns may differ.
To counter this, generalised and disease-speciﬁc instru-
ments could be used in combination to assess the full range
of aspects of health relevant to the population concerned.
In current evidence, it is not clear whether the psychoso-
cial morbidity associated with different management policies
differs between subgroups of women. There is some
evidence, albeit limited, that the psychosocial sequelae of
abnormal screening tests and follow-up may be more pro-
nounced in women of lower socio-economic status or with
poorer health literacy [11–13]. Drolet found that among
women with abnormal smear results, lower socio-economic
level was signiﬁcantly associated with having clinically
meaningful anxiety at 12 weeks [11]. In women referred
for colposcopy, Orbell found that those residents in areas
of higher social deprivation reported signiﬁcantly higher
anxiety scores [12], while Sharp found that low health liter-
acy was signiﬁcantly related to higher levels of distress [13].
No studies appear to have investigated whether the psycho-
logical impact of different management policies differs ac-
cording to women’s socio-economic status or health literacy.
Using data from the TOMBOLA trial, the primary aim
here was to compare the psychosocial morbidity (worries
and satisfaction with information and support) over 30
months of follow-up in women managed by the two alter-
native policies (cytological surveillance versus initial
colposcopy). Data were available for 3399 women. The
secondary aim was to investigate whether these psychoso-
cial outcomes differed in women with different levels of
post-school education, a marker of both socio-economic
status [14] and health literacy [15].
Methods
Participants and recruitment
The TOMBOLA trial design and sample size calculation
have been previously described [16]. In brief, women
resident in Grampian, Tayside or Nottingham, aged 20–
59 years with a routine cervical screening test showing
low-grade abnormalities (borderline nuclear abnormalties
(BNA) or mild dyskaryosis) within the National Health
Service Cervical Screening Programmes between October
1999 and October 2002 were recruited. Eligible women
could have had up to one additional BNA result in the
previous 3 years. Women with previous treatment for
proven or suspected lesions or who were pregnant were
not eligible. Women were randomised in equal propor-
tions to either cytological surveillance or initial colpos-
copy, using a telephone randomisation service provided
by the University of Aberdeen. All women were followed
up for 36 months, at which point they were invited to
attend for an exit examination, including colposcopy.
Management policies
Cytological surveillance consisted of repeat cytology tests
every 6 months in primary care. Women returned to
routine recall if they had three consecutive negative results.
Women with a cytology test showing moderate dyskar-
yosis or worse or three inadequate tests were referred for
colposcopy and managed according to local protocols.
Otherwise, women continued to receive six monthly
cytology tests. Women randomised to initial colposcopy
received an appointment to attend hospital for colposcopy
examination and were further randomised to immediate
treatment by large loop incision of the transformation zone
or 2–4 targeted punch biopsies and selective recall for
treatment. If an abnormal transformation zone was seen
at colposcopy, women received the intervention assigned
in this second randomisation. They were subsequently
followed up every 6 months with cytology tests in
primary care. If the transformation zone was normal, no
additional procedures were carried out at colposcopy, and
women were followed by annual cytology tests in primary
care. After three consecutive normal smears, women were
returned to management by routine recall. Cytological
results were monitored with subsequent management
(i.e. subsequent test date or referral to colposcopy) based
on these. Women re-referred to colposcopy during
follow-up attended local National Health Service clinics
where they were treated, if required, according to local
protocols.
Data collection
At recruitment, participants completed socio-demographic
and psychosocial questionnaires. Women were invited to
complete psychosocial questionnaires by post at 12, 18,
24 and 30 months post-recruitment. The psychosocial
questionnaire included HADS [17] and the process
outcome speciﬁc measure (POSM). The POSM was
developed within TOMBOLA and includes 14 questions
covering a range of issues identiﬁed as important by
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women with an abnormal smear who were undergoing
follow-up, including concerns about cervical cancer,
fertility and satisfaction with information and support
[10]. In brief, the questions in the recruitment question-
naire related to the time since receiving the cytology
result, and those in the follow-up questionnaires related
to the previous 4 weeks. Response options were in the
form of 5–7 level Likert scales. This instrument has been
shown to have acceptable psychometric properties and
good discriminant validity against the HADS [10,18].
Outcomes
The two outcomes of interest were derived from seven
‘core’ questions on the POSM [18]. A previously pub-
lished factor analysis [18] identiﬁed two constructs (Table
S1): follow-up related worries (four questions relating to
worries about cervical cancer, general health, the result of
the next cytology test and having sex) and satisfaction with
follow-up related information and support (three questions
relating to feeling well enough informed, being satisﬁed
with support from other people and how the woman felt
about herself). An exploratory factor analysis was under-
taken with varimax rotation, and the two factors explained
54.7% of the variance. Internal consistency of the resulting
factors was assessed using Cronbach’s alpha and was
0.769 for worries and 0.482 for information and support.
More details can be found in the previous publication [18].
Item responses for each question were standardised to
a score out of 100 (to account for a different number of
response options) [18]. For each construct, the standardised
item scores for the relevant questions were averaged and
standardised to a score out of 100. A higher score
indicates more worries or greater dissatisfaction with
information and support. To calculate scores for each
construct, women had to answer all questions which
formed that construct.
Statistical methods
Baseline characteristics were summarised for each man-
agement arm using mean and standard deviation (SD)
for continuous variables and number and percentage for
categorical variables. The focus was to determine whether,
on average, over the entire follow-up period, the psycho-
social morbidity differed between management arms. A
subsidiary interest was to determine whether there were
differences between arms in the pattern, or proﬁle of the
psychosocial morbidity during follow-up, and if so, at
which individual follow-up time-point differences were
most evident. Therefore, each longitudinal outcome (at
follow-up time points 12, 18, 24, 30 months) was analysed
using a linear mixed effects model (with unstructured
covariance) to allow for the correlation in repeated mea-
sures and allow all women who had responded to at least
one of the follow-up assessments to be included [19]. This
analysis approach assumes data are missing at random,
which was a plausible assumption in this setting. Models
were adjusted for minimisation variables (age group,
eligible smear, HPV status and trial centre) [20], baseline
(recruitment) score for worries or information and support
(as relevant) and depression at recruitment as measured by
the HADS because this differed signiﬁcantly between
arms [9]. Fixed effects for follow-up time point, manage-
ment arm, and an interaction between follow-up time
point and management arm were included; this interaction
term tested whether there were different proﬁles of
psychosocial morbidity over the entire follow-up period
between the two management arms. Models included
random effects for participants and interaction between
participants and follow-up time point to allow for random
intercepts and slope. All analyses were undertaken in SAS
v9.3 (SAS Institute, Cary, NC, USA). The models were
run initially for all women (primary analysis) and then
stratiﬁed by post-school education/training (secondary
analysis).
Results
Characteristics of participants
There were 3399 women eligible to complete the
psychosocial questionnaires, of whom 1703 (50.1%)
were randomised to cytological surveillance and 1696
(49.9%) to initial colposcopy (Figure S1). The manage-
ment arms were well balanced (Table S2) in terms of
women’s socio-demographic and clinical characteristics.
Slightly over 40% of women were aged 20–29, one
quarter were aged 30–39, one-ﬁfth were aged 40–49,
and less than 10% were aged 50–59 years. Just over
one quarter were recruited on the basis of a cytology test
showing mild dyskaryosis. Less than 10% had another
BNA cytology test in the previous 3 years. Ninety-ﬁve
per cent of women described their ethnic group as
‘white’. Just over a quarter had received no post-school
education, one-ﬁfth had received training through work,
almost 30% had obtained a qualiﬁcation other than a
degree from college or university and just under one
quarter had a degree.
Psychosocial morbidity over time
Figure 1 shows mean (+/ standard deviation) scores for
each of the outcome variables at each time point separately
for the twomanagement arms. Themean (SD) worries score
declined from 60.1 (19.9) at baseline to 42.6 (19.1) at 12
months in the colposcopy arm, and by 30 months, it had
fallen to 37.3 (17.8). The cytology arm at baseline was sim-
ilar, with mean (SD) 60.7 (18.6), but by 30 months, was 40
(18.7). The mean satisfaction with information and support
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score changed little over time and was 33.3 (15.2) with a
slight rise to 34.5 (15.9) at 12 months but returned to
around 33 by 30 months in the colposcopy arm. In the
cytology arm at baseline, the mean (SD) was 33.2 (15.7)
rising to 37.6 (17.0) at 12 months and dropping back down
to 34.7 (16.2) by 30 months.
Follow-up related psychosocial morbidity: comparison
of trial arms
Table 1 shows the results of the analysis comparing trial
arms overall and at each time point. Over the entire
observation period (12–30 months), the follow-up related
worries score in the colposcopy arm was, on average,
2.47 (95% CI 3.63 to 1.30) points lower than in the
cytology arm over the entire follow-up period, and this
was statistically signiﬁcant (p<0.001). The pattern of
follow-up related worries differed signiﬁcantly between
arms (p-value for interaction=0.013). A difference in the
worries score was evident at all time points; it was most
pronounced at 12 months and least pronounced (and not
signiﬁcant) at 24 months.
Over the entire observation period, satisfaction with
follow-up related information and support scores were,
on average, 2.35 (95% CI 3.32 to 1.38) points lower
in the colposcopy arm compared with the cytology arm
(p<0.001 for interaction). The interaction between time
point and management was signiﬁcant (p=0.013) indicat-
ing that the proﬁle of scores was different between arms.
Satisfaction with information and support scores were
lower (indicating greater satisfaction) at every time point
in those randomised to colposcopy compared with those
randomised to cytological surveillance, but at 24 months,
the difference was not statistically signiﬁcant.
Follow-up related psychosocial morbidity, by
post-school education
Figure S2 shows mean overall follow-up related worries
(Figure S2A) and satisfaction with information and
support (Figure S2B) scores at each follow-up time point
for women in the four post-school education categories.
The pattern of worries scores across follow-up was very
similar for the four post-school education groups.
Figure 1. Mean scores1 for worries and satisfaction with informa-
tion and support at recruitment and during follow-up (split by treat-
ment group).
1Maximum score for each outcome is 100; higher scores indicate
more worries or less satisfaction with information and support.
Table 1. Mean (SD) observed scores for each outcome at each follow-up time point and mixed effects model results for the differences
between colposcopy and cytology: primary analysis
Cytological surveillance Initial colposcopy Colposcopy minus cytology1 Time point-
management
arm interaction
p-valuen
Observed
mean (SD) n
Observed
mean (SD) Estimate 95% CI p-value
Follow-up related worries (n= 3198) 0.013
Across all time points 3198 2.47 (3.63, 1.30) <0.001
At individual time points
12 months 1119 46.8 (19.8) 1147 42.6 (19.1) 3.69 (5.14, 2.25) <0.001
18 months 997 43.8 (19.4) 1050 41.0 (18.9) 2.52 (4.03, 1.01) 0.001
24 months 915 39.8 (18.9) 965 39.0 (18.7) 1.13 (2.62, 0.36) 0.137
30 months 859 40.0 (18.7) 923 37.3 (15.2) 2.53 (4.08, 0.99) 0.001
Satisfaction with follow-up related
information and support
(n = 3199)
0.013
Across all time points 3199 2.35 (3.32, 1.38) <0.001
At individual time points
12 months 1113 37.6 (17.0) 1111 34.5 (15.9) 3.14 (4.46, 1.83) <0.001
18 months 994 37.0 (16.2) 1034 33.5 (14.6) 3.38 (4.67, 2.08) <0.001
24 months 936 35.2 (16.3) 986 34.4 (16.2) 1.13 (2.52, 0.27) 0.114
30 months 861 34.7 (16.2) 916 33.0 (14.6) 1.76 (3.15, 0.67) 0.013
1All models adjusted for age group, eligible smear, HPV status, trial centre, baseline depression and baseline score
CI, conﬁdence interval; SD, HPV, human papilloma virus; standard deviation.
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However, satisfaction with information and support scores
did differ across the four education groups, with lowest
scores (i.e. greatest satisfaction) obtained for those with
no post-school education.
Table S3 shows for each outcome, the average differ-
ence in scores over the entire observation period, between
trial arms, stratiﬁed by post-school education. For follow-
up related worries, in all four post-school education
groups, women in the colposcopy arm scored lower, but
the difference was only statistically signiﬁcant in women
with qualiﬁcations through work (average difference
4.39 points, p=0.002) and women with a degree (average
difference 2.36 points, p=0.031). Similarly, for satisfac-
tion with follow-up related information and support,
women in the colposcopy arm were more satisﬁed than
those in the cytological surveillance arm in all four sub-
groups. These differences reached statistical signiﬁcance
for those with no post-school education (p=0.005), those
with qualiﬁcations through work (p=0.016) and those
with a degree (0.023).
Discussion
The major ﬁnding was that follow-up psychosocial mor-
bidity was somewhat lower for women randomised to
initial colposcopy than to cytological surveillance. This
was seen consistently for both outcomes (follow-up
related worries and satisfaction with follow-up related
information and support).
For each outcome, the average difference in scores
between arms was 2 points or less. Given that the max-
imum score a woman could attain was 100, this differ-
ence is clearly modest. Further work is needed to
determine: whether a difference of this magnitude would
represent a clinically meaningful difference in psychoso-
cial well-being/morbidity at either the individual or the
population level; and whether any differences could
translate into further disbeneﬁts of screening such as
non-adherence to treatment, further follow-up, or subse-
quent rounds of primary screening, which may be associ-
ated with the development of precancerous or cancerous
lesions.
Some literature suggests that women may prefer more
‘active’ strategies for the follow-up of abnormal cytology
(such as colposcopy) to ongoing surveillance, but this is
not consistent, and a range of factors inﬂuence these
preferences, including cytology grade [8,21–24]. In
TOMBOLA, when women were asked (at the end of their
follow-up) about their satisfaction and preferences,
although the majority were content with the management
they had received, a minority would have preferred the
alternative option, and most of these would have preferred
colposcopy [25]. The results of the current study could pro-
vide an explanation for why this is the case (i.e. because of a
perception that it would reduce worries).
A range of explanations are possible for why the psy-
chosocial morbidity is lower in the colposcopy arm. It
has been suggested that the reasons for women preferring
active follow-up are that ‘treatment’ is performed more
rapidly and that it provides a more deﬁnitive result [26].
Together, these may provide women with resolution of
the psychosocial uncertainties associated with receipt of
an abnormal cytology result. While women in our study
managed by initial colposcopy did receive colposcopy
earlier than the ﬁrst surveillance smear (due at 6 months),
they may not have considered it to provide a deﬁnitive re-
sult because they were subsequently managed by 6 or 12
monthly cytology tests. A previous study has shown that,
among women with high-grade abnormal cytology, those
who received treatment had a greater decline in anxiety
compared with untreated women [11] suggesting the
possibility that the lower psychosocial morbidity in the
colposcopy arm could be because some women were
treated. Another possible explanation is that, at colpos-
copy and any subsequent treatment appointments, women
would have seen either a nurse colposcopist or a
gynaecologist. It is possible that seeing a ‘specialist’ is
more reassuring than seeing a general practitioner or
nurse in primary care, because attention by a specialist
promotes less distress because it is felt something is be-
ing done [27]. Colposcopy is a more invasive procedure,
and the process of examination and the possibility of
viewing their examination on a TV screen may provide
women with more reassurance than simply having a cytol-
ogy sample taken. Furthermore, the written and verbal in-
formation provided by a specialist, or the opportunity to
ask a specialist questions, may be more effective in resolv-
ing any uncertainties associated with abnormal cytology
and its follow-up. An individual’s coping skills and coping
styles inﬂuence psychological reactions to colposcopy [28]
and have implications for the framing of information about
management of abnormal cytology [29]. Although we did
not assess coping styles, it seems unlikely that our ﬁndings
could be explained by differences between arms in the dis-
tribution of women’s coping skills and styles; the
randomised design and large sample size mean that these
factors are most likely balanced across arms.
Although our primary interest was to consider the
entire follow-up period (12–30 months), in subsidiary
analyses, we investigated whether there were differences
between the arms at individual time points. For all out-
comes, the differences between the arms were largest at
the 12- and 18-month time points, which is consistent
with the pattern of women’s self-reported health during
follow-up [25]. It is also consistent with other work sug-
gesting that the quality of life impact of screening-related
events is generally fairly short-term [30]. It was notewor-
thy that for all three outcomes, there was no signiﬁcant
difference between the arms at 24 months; although the
average score was still lower in the colposcopy arm. A
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possible explanation is that by 24 months, some women
in the cytology arm may have been returned to routine
recall, and this ‘resolution’ may have resulted in lower
scores in that arm at that time point. However, if this
explanation holds, we might also expect to see no differ-
ence in scores at the 30-month time point, but in fact,
differences between arms were again apparent (although
smaller than at 12 and 18 months).
With the exception of satisfaction with information
and support in women who had obtained qualiﬁcations
through work, we found no evidence that the psychoso-
cial morbidity scores during follow-up differed in
women with different levels of post-school education (a
marker of socio-economic status and health literacy). In
contrast, Orbell et al., found that lower socio-economic
status was correlated with higher anxiety in women
who had colposcopy [12]; however, anxiety was
assessed 7 days after colposcopy, and socio-economic
status was based on an area-based measure of depriva-
tion; this is in contrast with the long-term assessment
and individual level measure of socio-economic status
in our study. Moreover, we found little evidence of a
differential effect of initial colposcopy and cytological
surveillance in relation to post-school education.
Across all these outcomes in all four post-school edu-
cation groups, women randomised to colposcopy con-
sistently scored lower on average than women
randomised to cytological surveillance, although this
difference was not always statistically signiﬁcant. This
suggests that if choosing between a follow-up policy
of initial colposcopy or cytological surveillance, deci-
sion makers need not be overly concerned that one
policy will differentially adversely affect particular
socio-economic groups.
Strengths/limitations
The major strengths of this randomised controlled trial are
its size, population basis, length of follow-up and longitu-
dinal assessment of outcomes. It is the ﬁrst randomised
study to have compared the psychosocial morbidity in
women managed by colposcopy with surveillance.
Although we addressed a range of issues identiﬁed by
women undergoing follow-up, women may have other
speciﬁc concerns and worries that were not considered
here, for example, future fertility or body image [31–33].
The outcomes (worries and satisfaction with information
and support) were derived from factor analysis. While the
reliability was good for the worries factor (Cα=0.769), it
was poorer for the satisfaction with information and
support factor (Cα=0.482) [18]. Although women were
recruited to the trial some time ago and primary HPV
testing is being implemented or considered in many
programmes [3], women with positive HPV tests will still
require triage or follow-up. For women not at sufﬁcient
risk for immediate colposcopy, options include repeat
cytology and/or HPV testing at 6 or 12 months; thus,
our ﬁndings remain relevant. In the sentinel sites in
England, cytology negative/high risk HPV positive
women will have repeat HPV testing after 12 months
[34]. Since TOMBOLA was conducted, the written
information provided to women is more standardised,
and there has been an explosion of other sources of
information, for example, on the internet. The likely
impact of this on women’s psychosocial well-being is
unknown.
Conclusions
Women with low-grade cytology managed by colpos-
copy compared with cytological surveillance have, on
average, a lower psychosocial morbidity during follow-
up. Although the difference is modest, implementation
of newer screening strategies, which incorporate a sur-
veillance pathway such as primary HPV screening, needs
to consider the information and support provided to
women.
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